BK Polyomavirus-Associated Carcinoma In Situ of the Renal Allograft: Balancing Oncologic Control and Graft Preservation.

Transplant ProcAug 22, 2026 (epub)

Emma Powell, Peter Lawlor, Melvyn Kuan

✦ AI-curated · Sources linked

Case in brief

A female renal transplant recipient in her 60s presented with biopsy-proven carcinoma in situ (CIS) of the urothelium within her renal allograft, following a history of BK polyomavirus nephropathy. Despite no visible lesions on imaging, a kidney-sparing approach using intrarenal gemcitabine and intensive surveillance was initiated. Although initial follow-up showed no progression, a repeat biopsy two years later revealed persistent CIS and ongoing BKPyV replication.

Diagnostic / clinical pearl

Clinicians should be aware that BK polyomavirus can be associated with carcinoma in situ in renal allografts, necessitating careful monitoring and management strategies that prioritize graft preservation.

Why it matters

This case highlights the complexities of managing BKPyV-associated malignancies in transplant recipients, emphasizing the need for tailored approaches that balance oncologic control with the preservation of renal function.

Source

Published in Transplant Proc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.